R-ALA vs Alpha-Lipoic Acid: Why the Better Form Often Absorbs Worse

The short answer

R-alpha-lipoic acid (R-ALA) is the enantiomer your body makes. Standard alpha-lipoic acid is a racemic 50/50 mixture of R and its mirror image S, which does not occur in nature at all. So the marketing pitch writes itself: buy the natural half, skip the synthetic filler.

The pitch is half right. R really is better absorbed, and it really is the biologically active form. But two facts complicate it badly. First, isolated free R-lipoic acid is unstable and polymerizes, so the premium bottle can deliver less usable material than the cheap one. Second, and less well known, supplemental lipoic acid of either form is not incorporated into the enzymes your mitochondria use it in. The “R matches what your mitochondria use” argument is true chemistry attached to the wrong mechanism.

Practical verdict: racemic ALA is the evidence-backed default, stabilized sodium R-lipoate is the defensible upgrade, and plain free R-ALA is the one option that is hard to justify. For what the compound does at all, see the alpha-lipoic acid pillar.

What R and S actually are

Alpha-lipoic acid has one chiral centre, which means it exists as two non-superimposable mirror images. Biology built itself around one of them. Every molecule of lipoic acid made by a human cell, a plant cell, or a bacterium is the R form. The S form is an artifact of the manufacturing process: chemical synthesis produces both enantiomers in equal amounts, and separating them costs money, so the cheap product contains both.

This is worth stating plainly because it sets up the intuition that drives the whole category. If your body only makes R, and only R fits the enzymes, then half of a racemic capsule looks like inert padding at best and interference at worst. That intuition is reasonable. It is also where the argument starts to come apart.

The mechanism problem nobody mentions

Here is the part that changes how you should read every R-ALA sales page.

Lipoic acid’s famous job is as a cofactor in the mitochondrial enzyme complexes that feed the energy cycle: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, and the glycine cleavage system. In that role it is not floating around loose. It is covalently bound to a lysine residue on the enzyme itself, as lipoyllysine.

And crucially, cells do not build that cofactor from free lipoic acid. The pathway starts with octanoic acid already attached to the target enzyme, and lipoyl synthase then inserts two sulfur atoms in place. The cofactor is assembled on site. Exogenous free lipoic acid, whether R, S, or both, cannot be retrofitted into those complexes.

⚠ CLAIM (educational): Supplemental lipoic acid does not top up the protein-bound lipoyl cofactor in mitochondrial dehydrogenase complexes, because that cofactor is synthesized in place from enzyme-bound octanoic acid. Supplemental ALA acts instead as a free redox-active and signalling molecule. Basis: Shay 2009; Linus Pauling Institute lipoic acid review. Lane: educational.

So what does a supplement actually do? It circulates briefly as a free molecule with strong redox chemistry, gets reduced to dihydrolipoic acid, influences the cell’s own antioxidant systems, raises intracellular cysteine availability for glutathione synthesis, and activates the Nrf2 pathway, the same pathway we cover in sulforaphane and Nrf2. That is a real and interesting mechanism. It just is not “refilling your mitochondrial cofactor,” and once you accept that, the argument that R is superior because it is what the enzymes use loses most of its force. Both forms are acting as free-floating redox agents, not as cofactor replacements.

Where R genuinely wins: absorption

Strip away the cofactor story and one real advantage survives. R is absorbed better than S.

When healthy volunteers take a single oral dose of racemic lipoic acid, peak plasma concentrations of the R enantiomer run roughly 40 to 50 percent higher than those of S. Same capsule, same moment, measurably different exposure. That is a genuine pharmacokinetic difference favouring R, confirmed with enantioselective assays rather than inferred.

It is worth being precise about what this does and does not mean. It means that in a 600 mg racemic capsule, the R content behaves as though it were somewhat more than half the dose. It does not mean the S half is doing nothing, and it does not tell you that a pure R product will outperform, because that depends entirely on whether the pure R product survives the journey to your mouth intact.

Where R loses: it falls apart

Free R-lipoic acid has a low melting point and a strong tendency to polymerize, linking to itself into larger molecules, a process accelerated by warmth, moisture, and time. It also has poor aqueous solubility. Polymerized lipoic acid is not absorbed the way the monomer is, and it does not announce itself: it weighs the same, it sits in the same capsule, and the label still says 300 mg.

Racemic material is more stable, which is one of the quietly useful things about having the S enantiomer present. The commercial answer for R products is to convert the acid to a salt, most commonly sodium R-lipoate, which is both stable and readily soluble.

The pharmacokinetic difference that fix produces is not subtle. In work by Carlson and colleagues, 600 mg of sodium R-lipoate produced mean peak plasma concentrations around 16 µg/mL with a median time to peak near 15 minutes, while paired comparisons with the free acid landed near 1 µg/mL. Read that as an indictment of the free acid rather than a miracle of the salt: it suggests unstabilized R-lipoic acid was barely getting absorbed at all.

The usual honesty caveat applies. That study was small, appeared in Alternative Medicine Review, and had ties to a commercial developer of sodium R-lipoate, so the precise multiples deserve caution. The underlying chemistry, that free R-lipoic acid polymerizes and the salt does not, is not in dispute.

The evidence gap that settles it

Everything above is chemistry and blood levels. The question that actually matters is which form makes people better off, and on that the picture is lopsided.

Essentially all the substantial human trial evidence for alpha-lipoic acid used racemic material. SYDNEY 2, which established the 600 mg reference dose, used racemic ALA. NATHAN 1, the four-year study, used racemic ALA. The meta-analyses aggregate racemic trials. In Germany, where thioctic acid is an approved prescription drug rather than a supplement, the approved product is racemic.

There is no comparable outcome evidence for R-ALA or sodium R-lipoate. Higher plasma peaks are a plausible reason to expect an advantage, and plausible reasons to expect advantages have a long history of not surviving trials. Until someone runs the head-to-head, the honest statement is that the better-absorbed form has never been shown to work better.

	Racemic ALA (R/S)	Free R-ALA	Sodium R-lipoate
Occurs in nature	Half of it	Yes	As the R lipoate ion, yes
Absorption	Moderate; R fraction peaks 40 to 50% above S	Poor and unpredictable once polymerized	High peaks, very fast
Shelf stability	Good	Poor; polymerizes with heat and time	Good
Human outcome trials	Extensive, including SYDNEY 2 and NATHAN 1	None of consequence	None of consequence
Cost	Low	High	Highest
Verdict	The sensible default	Hard to justify	Defensible upgrade, unproven benefit

Is the S enantiomer bad for you?

This is the strongest version of the R-ALA argument, and it deserves a straight answer: probably not, and the evidence that it is harmful is thin.

Some laboratory work has suggested the S form is less active in certain systems, and it has been proposed that S might compete with R for uptake or for enzymatic reduction. That is a coherent hypothesis. What is missing is evidence that it matters at real doses in real people. Racemic ALA, containing a full 300 mg of S in every 600 mg capsule, is the material that produced the positive trial results and carries decades of clinical use, including as a prescription drug. If the S enantiomer were meaningfully sabotaging things, that is a strange result to keep getting.

There is also a practical point in S’s favour. Its presence appears to help keep the R form from polymerizing, which is precisely the failure mode that makes isolated R products unreliable. The synthetic half you are being told to pay to remove is doing some quiet stabilizing work.

So which should you take?

If you want the option with the strongest evidence behind it, take racemic alpha-lipoic acid at 600 mg. It is what the research used, it is stable, and it is cheap enough that the cost question barely arises.

If you specifically want better absorption and accept you are paying for a pharmacokinetic advantage rather than a demonstrated clinical one, take a named stabilized salt, in practice sodium R-lipoate, from a company that will tell you whether its stated milligrams include the sodium.

What is genuinely hard to defend is free, unstabilized R-ALA at a premium price. You are paying more for the enantiomer with the absorption advantage and simultaneously buying the format most likely to have degraded before you opened it. If a label says R-ALA and will not name a salt, that is the product to walk past. The full label checklist is in the alpha-lipoic acid buying guide, and dose and timing are covered in how much alpha-lipoic acid per day.

One last framing note. This is a decision about a supplement whose overall evidence is narrow: convincing in one clinical context, modest in most others. Choosing between enantiomers is a smaller lever than choosing whether the compound earns a place in your routine at all, which is the question our evidence-graded supplement guide exists to answer.

Educational information only, not medical advice, and not evaluated by the FDA. Alpha-lipoic acid is not a treatment for any disease, and nothing here is a dosing protocol. Talk to a clinician before supplementing, particularly if you take diabetes medication or insulin, since alpha-lipoic acid can lower blood sugar and has been linked in rare cases to insulin autoimmune syndrome in genetically susceptible people. Keep supplements out of reach of children.